Evidence map›Paper›PMID 38598028›Full record

ArticleClinical and experimental medicine2024

Antinuclear antibodies may predict the development of immune-related adverse events in asymptomatic patients treated with immune checkpoint inhibitors: results from a single-center cohort.

Fulvia Ceccarelli, Francesco Natalucci, Licia Picciariello, Alessio Cirillo, Giulio Olivieri, Margherita Veroli, Simona Pisegna, Claudia Ciancarella, Alain Gelibter, Vincenzo Picone and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Fulvia CeccarelliDepartment of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Arthritis Center, Rheumatology, Sapienza University of Rome, Rome, Italy.
Francesco NatalucciDepartment of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Arthritis Center, Rheumatology, Sapienza University of Rome, Rome, Italy. francesco.natalucci@uniroma1.it.
Licia PicciarielloDepartment of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Arthritis Center, Rheumatology, Sapienza University of Rome, Rome, Italy.
Alessio CirilloDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
Giulio OlivieriResearch Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Margherita VeroliDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
Simona PisegnaDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
Claudia CiancarellaDepartment of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Arthritis Center, Rheumatology, Sapienza University of Rome, Rome, Italy.
Alain GelibterDivision of Medical Oncology B, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
Vincenzo PiconeDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
Daniele SantiniDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
Andrea BotticelliDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
Fabrizio ContiDepartment of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Arthritis Center, Rheumatology, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aim at investigating the association between subclinical autoimmunity and immune-related adverse events (irAEs) in a cohort of patients treated by immune checkpoint inhibitors for solid metastatic cancer. In the context of an oncology/rheumatology outpatient clinic, we evaluated patients treated with anti-PD-1 or anti-PD-L1. Before treatment, each patient underwent a physical evaluation and a blood sample to identify the presence of a set of autoantibodies. Indeed, all the patients were followed during treatment to identify irAEs and to assess the association with autoantibodies. Fifty-one patients (M/F 16/35; median age 70 years, IQR 16.5) were evaluated; 34.8% of patients showed ANA positivity, 6.5% ENA positivity (anti-SSA), 4.3% Ratest positivity, and 2.1% (one patient) ACPA positivity. During a median period of 21 months (IQR 38.75), 39.2% of patients developed irAEs. Musculo-skeletal manifestations, in particular arthritis, were the most frequent. We found a significant association between the positivity for ANA and the development of irAES (p = 0.03, RR 2.01, 95% CI 1.03-3.92). Furthermore, the progression-free survival was significantly longer in patients developing irAEs compared to those who are not experiencing these events (p = 0.007). This study underlines the potential role of ANA positivity as a predictive biomarker for the development of irAEs.

Indexed as

Antibodies, AntinuclearArthritisAgedAutoantibodiesAutoimmunityHumansImmune Checkpoint InhibitorsAntibodies, AntinuclearAutoantibodiesImmune Checkpoint InhibitorsAdverse eventsAnti-nuclear antibodiesBiomarkersImmune-checkpoints inhibitors

Identifiers

PMID38598028
PMCPMC11006777
OpenAlexW4394678490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.